Wu Zhongren, Cappiello Maria G, Scott Boyd B, Bukhtiyarov Yuri, McGeehan Gerard M
Vitae Pharmaceuticals Inc., Discovery Biology, Fort Washington, PA, 19034, USA.
BMC Biochem. 2008 Jun 26;9:19. doi: 10.1186/1471-2091-9-19.
The renin-angiotensin-aldosterone system (RAS) cascade is a major target for the clinical management of hypertension. Although inhibitors of various components of this cascade have been developed successfully, development of renin inhibitors has proven to be problematic. The development of these inhibitors has been hindered by poor bioavailability and complex synthesis. However, despite the challenges of designing renin inhibitors, the enzyme remains a promising target for the development of novel treatments for hypertension. X-ray crystallographic data could greatly assist the design and development of these inhibitors. Here we describe the purification and characterization of recombinant human renin for x-ray crystallization studies.
A cDNA encoding the full length of native human preprorenin (406 amino acid residues) was introduced into the HEK-293 cell line. A clonal cell line expressing prorenin was generated and grown under serum free conditions in a hollow fiber bioreactor. Prorenin was constitutively secreted and purified directly from the conditioned medium. Concanavalin A chromatography effectively enriched and purified prorenin to 90% homogeneity in a single step. Prorenin was converted to active renin by trypsin digestion to remove the propeptide. Active renin was further purified using a cation exchange column followed by a gel filtration column. Biochemical characterization of the recombinant enzyme showed both binding and catalytic properties were essentially identical to previously reported activities for purified renin. Crystals were grown using this material in our X-ray structure studies, and high resolution diffraction was obtained.
This present work describes a simple and efficient method for the generation and purification of active human renin. The protein is highly pure and is suitable for supporting structural biology efforts.
肾素 - 血管紧张素 - 醛固酮系统(RAS)级联反应是高血压临床治疗的主要靶点。尽管已成功开发出该级联反应各组分的抑制剂,但肾素抑制剂的开发却存在问题。这些抑制剂的开发受到生物利用度差和合成复杂的阻碍。然而,尽管设计肾素抑制剂存在挑战,但该酶仍是开发新型高血压治疗药物的一个有前景的靶点。X射线晶体学数据可极大地辅助这些抑制剂的设计和开发。在此,我们描述用于X射线结晶研究的重组人肾素的纯化和表征。
将编码天然人前肾素全长(406个氨基酸残基)的cDNA导入HEK - 293细胞系。生成了表达肾素原的克隆细胞系,并在中空纤维生物反应器中无血清条件下培养。肾素原组成性分泌,并直接从条件培养基中纯化。伴刀豆球蛋白A层析在一步中有效地将肾素原富集并纯化至90%的同质性。通过胰蛋白酶消化去除前肽,将肾素原转化为活性肾素。活性肾素进一步通过阳离子交换柱随后是凝胶过滤柱进行纯化。重组酶的生化表征表明,其结合和催化特性与先前报道的纯化肾素的活性基本相同。在我们的X射线结构研究中使用该材料生长出晶体,并获得了高分辨率衍射。
本研究描述了一种简单有效的方法来生成和纯化活性人肾素。该蛋白质高度纯净,适用于支持结构生物学研究。